HQY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HQY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. HealthEquity's accounts receivables for the quarter that ended in Jan. 2024 was $104.9 Mil.
Accounts receivable can be measured by Days Sales Outstanding. HealthEquity's Days Sales Outstanding for the quarter that ended in Jan. 2024 was 36.48.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. HealthEquity's Net-Net Working Capital per share for the quarter that ended in Jan. 2024 was $-7.50.
The historical data trend for HealthEquity's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthEquity Annual Data | |||||||||||||||||||||
Trend | Jan15 | Jan16 | Jan17 | Jan18 | Jan19 | Jan20 | Jan21 | Jan22 | Jan23 | Jan24 | |||||||||||
Accounts Receivable | Get a 7-Day Free Trial | 70.86 | 72.77 | 87.43 | 96.84 | 104.89 |
HealthEquity Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Accounts Receivable | Get a 7-Day Free Trial | 96.84 | 98.41 | 92.58 | 96.18 | 104.89 |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
HealthEquity's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 104.893 | / | 262.387 | * | 91 |
= | 36.48 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), HealthEquity's accounts receivable are only considered to be worth 75% of book value:
HealthEquity's Net-Net Working Capital Per Share for the quarter that ended in Jan. 2024 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (403.979 | + | 0.75 * 104.893 | + | 0.5 * 0 | - | 1128.769 |
- | 0 | - | 0) | / | 86.127 | ||
= | -7.50 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of HealthEquity's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Delano Ladd | officer: Executive VP, GC & Corp. Secy. | 15W. SCENIC POINTE DR., SUITE 100, DRAPER UT 84020 |
Ian Sacks | director | TOWERBROOK CAP., PARK AVENUE TOWER, 65 E 55TH ST., 27TH FLOOR, NEW YORK NY 10022 |
Elimelech Rosner | officer: EVP, Chief Technology Officer | 5196 BELMORE COURT, SUWANEE GA 30024 |
Stephen Neeleman | director, officer: Founder and Vice Chairman | 15 W. SCENIC POINTE DR., STE. 100, DRAPER UT 84020 |
Tyson D. Murdock | officer: EVP & CFO | 2275 S. 2200 E., SALT LAKE CITY UT 84109 |
Jon Kessler | director, officer: President and CEO | 15 W. SCENIC POINTE DR., STE. 100, DRAPER UT 84020 |
Frank Corvino | director | GREENWICH HOSPITAL, 5 PERRYRIDGE ROAD, GREENWICH CT 06830 |
Larry L Trittschuh | officer: EVP Chief Security Officer | 1051 RUNNYMEDE ROAD, OAKWOOD OH 45419 |
James M Lucania | officer: EVP & CFO | 101 WOLF DRIVE, THOROFARE NJ 08086 |
Gayle Furgurson Wellborn | director | 123 TORRENCE CHAPEL ROAD, MOORESVILLE NC 28117 |
Debra Charlotte Mccowan | director | 1436 CABRILLO AVENUE, BURLINGAME CA 94010 |
Paul Black | director | 400 WOOD ROAD, BRAINTREE MA 02184 |
Edward Bloomberg | officer: Chief Operating Officer | 13207 WINDSOR STREET, LEAWOOD KS 66209 |
Rajesh Natarajan | director | 7500 DALLAS PARKWAY, SUITE 700, PLANO TX 75024 |
Evelyn S Dilsaver | director | C/O LONGS DRUG STORES CORPORATION, 141 NORTH CIVIC DRIVE, WALNUT CREEK CA 94596 |
From GuruFocus
By PurpleRose PurpleRose • 07-15-2022
By GuruFocus Research • 09-06-2023
By GuruFocus Research • 09-06-2023
By sperokesalga sperokesalga • 06-14-2023
By Marketwired • 09-19-2023
By Marketwired • 07-18-2023
By GuruFocus Research • 09-21-2023
By Marketwired • 09-19-2023
By Stock market mentor Stock market mentor • 01-09-2023
By PurpleRose PurpleRose • 08-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.